Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, Brian J. Smith, Caitlin D. Lemke-Miltner, Zhaoming Wang, Umar Farooq, George J. Weiner

Blood (2024) 143 (18): 1816–1824.

https://doi.org/10.1182/blood.2023023370

Published: 2024

Includes: Supplemental data

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Blood (2017) 130 (Supplement 1): 4115.

https://doi.org/10.1182/blood.V130.Suppl_1.4115.4115

Published: 2017

Journal Articles

Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials

Matthew J Maurer, MS, Brian K Link, MD, Thomas M. Habermann, MD, Carrie A. Thompson, MD, Cristine Allmer, BS, Patrick B. Johnston, MD PhD, Ivana Micallef, MD, David J. Inwards, MD, Umar Farooq, MD, William R. Macon, MD, Sergei Syrbu, MD, Andrew L Feldman, MD, Susan L. Slager, PhD, George J. Weiner, MD, Stephen Ansell, MD PhD, James R Cerhan, MD PhD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 3034.

https://doi.org/10.1182/blood.V128.22.3034.3034

Published: 2016

Journal Articles

Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist

Caitlin D Lemke, PhD, Sue E Blackwell, MS, Arthur M Krieg, MD, Aliasger Salem, PhD, George J Weiner, MD

Blood (2016) 128 (22): 3023.

https://doi.org/10.1182/blood.V128.22.3023.3023

Published: 2016

Journal Articles

Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

Sean I. Tracy, MD PhD, Matthew J Maurer, MS, Thomas E. Witzig, MD, Matthew T. Drake, MD PhD, Stephen Ansell, MD PhD, Grzegorz S. Nowakowski, MD, David James Inwards, MD, Carrie A Thompson, MD, Patrick B. Johnston, MD PhD, Ivana Micallef, MD, Cristine Allmer, BS, William R. Macon, MD, George J Weiner, MD, Susan L. Slager, PhD, Thomas M. Habermann, MD, Brian K Link, MD, James R Cerhan, MD PhD

Blood (2016) 128 (22): 1104.

https://doi.org/10.1182/blood.V128.22.1104.1104

Published: 2016

Journal Articles

No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era

Sean I. Tracy, MDPhD, Thomas M. Habermann, MD, Andrew L Feldman, MD, Matthew J Maurer, MS, Ahmet Dogan, Usha S Perepu, MBBS, Sergei Syrbu, MD, Stephen Ansell, MD PhD, Carrie A Thompson, MD, George J Weiner, MD, Cristine Allmer, BS, Susan L. Slager, PhD, Thomas E. Witzig, MD, James R Cerhan, MD PhD, Brian K Link, MD

Blood (2016) 128 (22): 107.

https://doi.org/10.1182/blood.V128.22.107.107

Published: 2016

Journal Articles

Novel IL-2Ralpha (CD25)-Binding RNA Aptamer to Target T Regulatory Cells

Suresh Veeramani, DVM, PhD, Sue E Blackwell, MS, William H Thiel, PhD, Paloma H Giangrande, PhD, George J Weiner, MD

Blood (2016) 128 (22): 3697.

https://doi.org/10.1182/blood.V128.22.3697.3697

Published: 2016

Journal Articles

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Blood (2015) 126 (23): 703.

https://doi.org/10.1182/blood.V126.23.703.703

Published: 2015

Journal Articles

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Aneel Paulus, MDMS, Sharoon Akhtar, MPhil, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Pooja Advani, MBBS, Thomas E. Witzig, MD, George J Weiner, MD, Sikander Ailawadhi, MD, Joachim Gullbo, MD PhD, Stig Linder, PhD, Geraldo Otero-Colon, Kasyapa S. Chitta, PhD, Asher Alban Chanan-Khan, MD

Blood (2015) 126 (23): 1557.

https://doi.org/10.1182/blood.V126.23.1557.1557

Published: 2015

Journal Articles

Three Steps to Breaking Immune Tolerance: A Microparticle Approach

Amani Makkouk, MS, Vijaya B Joshi, PhD, Caitlin D Lemke, PhD, Amaraporn Wongrakpanich, BS, Alicia K Olivier, DVM, PhD, Sue E Blackwell, MS, Aliasger K Salem, PhD, George J. Weiner, MD

Blood (2014) 124 (21): 4504.

https://doi.org/10.1182/blood.V124.21.4504.4504

Published: 2014

Journal Articles

Intratumoral Inhibition of C5a Using Anti-C5a Monoclonal Antibody Inhibits Lymphoma Progression

Suresh Veeramani, DVM, PhD, George J. Weiner, MD

Blood (2014) 124 (21): 4506.

https://doi.org/10.1182/blood.V124.21.4506.4506

Published: 2014

Journal Articles

Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia

Nandita Bose, PhD, Clive S. Zent, MD, Betsy R. LaPlant, MS, Nadine Ottoson, Steven Leonardo, PhD, George J Weiner, MD, Stephen M. Ansell, MD PhD

Blood (2014) 124 (21): 5662.

https://doi.org/10.1182/blood.V124.21.5662.5662

Published: 2014

Journal Articles

Intestinal Helminth Colonization Regulates Lethal Graft Versus Host Disease and Preserves Graft Versus Tumor in Bone Marrow Transplanted Mice

Yue Li, MDPhD, Hung-lin Chen, Nadine Bannick, Michael D. Henry, PhD, David E. Elliott, MDPhD, George J Weiner, MD, Bruce R. Blazar, MD, M. Nedim Ince, MD

Blood (2014) 124 (21): 1102.

https://doi.org/10.1182/blood.V124.21.1102.1102

Published: 2014

Journal Articles

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

Clive S. Zent, MD, Betsy R LaPlant, MS, Wenting Wu, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Michael J. Conte, PA-C, George J. Weiner, MD, Thomas E Witzig, MD

Blood (2013) 122 (21): 1641.

https://doi.org/10.1182/blood.V122.21.1641.1641

Published: 2013

Journal Articles

C5a Complement Depletion Suppresses In Vivo B Lymphoma Progression and Enhances Development Of Cellular Anti-Tumor Immune Response

Suresh Veeramani, DVM, PhD, George J. Weiner, MD

Blood (2013) 122 (21): 1837.

https://doi.org/10.1182/blood.V122.21.1837.1837

Published: 2013

Journal Articles

Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab

Laura M Rogers, PhD, Laura S. Jacobus, MS, Anna M Button, MS, Brian K Link, MD, Thomas M Habermann, MD, Thomas E Witzig, MD, James R Cerhan, MD, PhD, George J. Weiner, MD

Blood (2013) 122 (21): 4288.

https://doi.org/10.1182/blood.V122.21.4288.4288

Published: 2013

Journal Articles

Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era

James R Cerhan, MD, PhD, Grzegorz S. Nowakowski, MD, Matthew J Maurer, MS, Bridget Charbonneau, PhD, Herve Ghesquieres, MD, PhD, Anne J. Novak, Ph.D., Yan W Asmann, PhD, Ahmet Dogan, MD, PhD, Svetomir N. Markovic, MD, PhD, Carrie A. Thompson, MD, Stephen M. Ansell, M.D., Ph.D., George J. Weiner, MD, Brian K Link, MD, Thomas M Habermann, MD, Susan L Slager, PhD

Blood (2012) 120 (21): 149.

https://doi.org/10.1182/blood.V120.21.149.149

Published: 2012

Journal Articles

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

Brian K Link, MD, Matthew J Maurer, MS, Grzegorz S. Nowakowski, MD, Stephen M Ansell, MD, PhD, William R Macon, MD, Sergei I Syrbu, MD, Susan L Slager, PhD, Carrie A. Thompson, MD, David J. Inwards, MD, Patrick B. Johnston, MD, PhD, Joseph P. Colgan, MD, Thomas E. Witzig, MD, George J Weiner, Thomas M. Habermann, James R Cerhan, MD, PhD

Blood (2012) 120 (21): 1546.

https://doi.org/10.1182/blood.V120.21.1546.1546

Published: 2012

Journal Articles

EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE

Usha Perepu, MBBS, Ahmet Dogan, MD, PhD, Matthew J Maurer, MS, Cristine Allmer, BS, Carrie A. Thompson, MD, Stephen M Ansell, Sergei I Syrbu, MD, Susan L Slager, PhD, Thomas E. Witzig, MD, George J. Weiner, MD, Thomas M. Habermann, James R Cerhan, MD, PhD, Brian K Link, MD

Blood (2012) 120 (21): 1604.

https://doi.org/10.1182/blood.V120.21.1604.1604

Published: 2012

NARROW

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials

Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist

Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma

No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era

Novel IL-2Ralpha (CD25)-Binding RNA Aptamer to Target T Regulatory Cells

VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia

Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma

Three Steps to Breaking Immune Tolerance: A Microparticle Approach

Intratumoral Inhibition of C5a Using Anti-C5a Monoclonal Antibody Inhibits Lymphoma Progression

Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia

Intestinal Helminth Colonization Regulates Lethal Graft Versus Host Disease and Preserves Graft Versus Tumor in Bone Marrow Transplanted Mice

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

C5a Complement Depletion Suppresses In Vivo B Lymphoma Progression and Enhances Development Of Cellular Anti-Tumor Immune Response

Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab

Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era

Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource

EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only